By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ERS Genomics 

88 Harcourt Street

Dublin 2      Ireland
Phone: +353-01-539-0082 Fax: n/a


ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by co-inventor and co-owner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.

CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods.




Scientific Advisor and Co-Founder: Dr. Emmanuelle Charpentier

Chairman of the Board and Co-Founder: Shaun Foy

CEO: Eric Rhodes


Please click here for ERS Genomics' technology.

Key Statistics

Ownership: Private

Web Site: ERS Genomics


Company News
CRISPR (CRSP), Intellia, Caribou Biosciences And ERS Genomics Announce Appellate Brief Seeking Reversal Of U.S. Patent Board Decision On CRISPR/Cas9 Gene Editing 7/26/2017 10:39:09 AM
Taconic Biosciences Secures CRISPR License From ERS Genomics 5/31/2017 7:24:24 AM
Oxford Genetics Licenses CRISPR Gene Editing Technology From ERS Genomics To Extends Its Synthetic Biology Capabilities 5/9/2017 8:09:42 AM
Patent Fight Continues as CRISPR (CRSP), Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision 4/13/2017 8:19:07 AM
ERS Genomics Release: European Patent Office To Grant Broad Claims On Patent Covering CRISPR-Cas9 Gene Editing Technology 3/28/2017 6:58:41 AM
CRISPR (CRSP), Intellia, Caribou Biosciences And ERS Genomics Provide Update On CRISPR/Cas9 U.S. Patent Interference Proceedings And Grants Of Corresponding Patents In The U.K. 2/16/2017 7:06:22 AM
ERS Genomics And Knudra Transgenics Sign License Agreement On CRISPR-Cas9 Genome Editing Patents For Model-Organisms 11/2/2016 10:22:32 AM
ERS Genomics And Evolva (EVE.SW) Sign License Agreement On CRISPR-Cas9 Genome Editing Patents For Industrial Applications 10/27/2016 11:52:10 AM